The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2017 May 27

PMID 28548071

Citations 6

Authors

Luigi Ruco

Stefania Scarpino

Affiliations

Soon will be listed here.

Abstract

The oncogene encodes for Met protein, a trans-membrane tyrosine kinase identified as the high affinity receptor for hepatocyte growth factor (HGF). Immunohistochemical studies have demonstrated that Met protein is intensely expressed in tumor cells of >95% cases of thyroid papillary carcinoma. High density of Met protein in tumor cells is the result of increased transcription of a normal gene, probably due to a combination of intracellular and extracellular signals. Over-expression of Met protein is more pronounced at the invading front of the tumor and can profoundly affect the tumorigenesis of papillary carcinoma of the thyroid. In fact, Met protein-positive papillary carcinoma cells are highly responsive to hepatocyte growth factor (HGF), which is effective in stimulating tumor cell adhesion, migration and invasiveness. In addition, HGF stimulation of papillary carcinoma of the thyroid (PTC) cells causes up-regulation of COX-2 and down-regulation of CD82/KAI-1; both these molecules have a major role in controlling tumor cell invasiveness. Finally, HGF stimulation of tumor cells may significantly affect the tumor microenvironment. In fact, HGF induces tumor cells to release chemokines active in the recruitment of dendritic cells, and is involved in regulating the production of proangiogenic factors.

Citing Articles

Impact of Neuron-Derived HGF on c-Met and KAI-1 in CNS Glial Cells: Implications for Multiple Sclerosis Pathology.

Takano T, Takano C, Funakoshi H, Bando Y Int J Mol Sci. 2024; 25(20).

PMID: 39457044 PMC: 11509024. DOI: 10.3390/ijms252011261.

Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the .

Sahakian N, Castinetti F, Romanet P Cancers (Basel). 2023; 15(19).

PMID: 37835559 PMC: 10572078. DOI: 10.3390/cancers15194865.

High COX-2 immunostaining in papillary thyroid carcinoma is associated with adverse survival outcomes.

Al-Maghrabi J, Gomaa W Ann Saudi Med. 2022; 42(6):359-365.

PMID: 36444921 PMC: 9706716. DOI: 10.5144/0256-4947.2022.359.

Thyroid Cancer and Circadian Clock Disruption.

Malaguarnera R, Ledda C, Filippello A, Frasca F, Francavilla V, Ramaci T Cancers (Basel). 2020; 12(11).

PMID: 33114365 PMC: 7690860. DOI: 10.3390/cancers12113109.

The Emerging Role of Insulin Receptor Isoforms in Thyroid Cancer: Clinical Implications and New Perspectives.

Vella V, Malaguarnera R Int J Mol Sci. 2018; 19(12).

PMID: 30513575 PMC: 6321330. DOI: 10.3390/ijms19123814.

References

Wang R, Kobayashi R, Bishop J . Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc Natl Acad Sci U S A. 1996; 93(16):8425-30. PMC: 38687. DOI: 10.1073/pnas.93.16.8425. View

Ivan M, Bond J, Prat M, Comoglio P, Wynford-Thomas D . Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene. 1997; 14(20):2417-23. DOI: 10.1038/sj.onc.1201083. View

Trusolino L, Cavassa S, Angelini P, Ando M, Bertotti A, Comoglio P . HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J. 2000; 14(11):1629-40. DOI: 10.1096/fj.14.11.1629. View

Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y . BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003; 22(41):6455-7. DOI: 10.1038/sj.onc.1206739. View

Takano T, Matsuzuka F, Sumizaki H, Kuma K, Amino N . Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma. Cancer Res. 1997; 57(17):3792-7. View

Giordano S, Ponzetto C, Di Renzo M, Cooper C, Comoglio P . Tyrosine kinase receptor indistinguishable from the c-met protein. Nature. 1989; 339(6220):155-6. DOI: 10.1038/339155a0. View

Scarpino S, Cancellario dAlena F, Di Napoli A, Ballarini F, Prat M, Ruco L . Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis. J Pathol. 2003; 199(2):243-50. DOI: 10.1002/path.1278. View

Mazhar D, Gillmore R, Waxman J . COX and cancer. QJM. 2005; 98(10):711-8. DOI: 10.1093/qjmed/hci119. View

Soares P, Trovisco V, Rocha A, Lima J, Castro P, Preto A . BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003; 22(29):4578-80. DOI: 10.1038/sj.onc.1206706. View

10.

Belfiore A, Gangemi P, Costantino A, Russo G, Santonocito G, Ippolito O . Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab. 1997; 82(7):2322-8. DOI: 10.1210/jcem.82.7.4104. View

11.

Huang Y, Prasad M, Lemon W, Hampel H, Wright F, Kornacker K . Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A. 2001; 98(26):15044-9. PMC: 64980. DOI: 10.1073/pnas.251547398. View

12.

Seth A, Park M, Copeland T, Oroszlan S, Woude G . Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci U S A. 1988; 85(1):21-5. PMC: 279473. DOI: 10.1073/pnas.85.1.21. View

13.

Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio P . Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003; 3(4):347-61. DOI: 10.1016/s1535-6108(03)00085-0. View

14.

Schaffler A, Palitzsch K, Seiffarth C, Hohne H, Riedhammer F, Hofstadter F . Coexistent thyroiditis is associated with lower tumour stage in thyroid carcinoma. Eur J Clin Invest. 1998; 28(10):838-44. DOI: 10.1046/j.1365-2362.1998.00363.x. View

15.

Boccaccio C, Gaudino G, Gambarotta G, Galimi F, Comoglio P . Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem. 1994; 269(17):12846-51. View

16.

Webb C, Taylor G, Jeffers M, Fiscella M, Oskarsson M, Resau J . Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene. 1998; 17(16):2019-25. DOI: 10.1038/sj.onc.1202135. View

17.

Naldini L, Vigna E, Narsimhan R, Gaudino G, Zarnegar R, Michalopoulos G . Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene. 1991; 6(4):501-4. View

18.

Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S . Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid. 1998; 8(3):197-202. DOI: 10.1089/thy.1998.8.197. View

19.

Ruggeri R, Vitarelli E, Barresi G, Trimarchi F, Benvenga S, Trovato M . HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization. Histol Histopathol. 2011; 27(1):113-21. DOI: 10.14670/HH-27.113. View

20.

Nusrat A, Parkos C, Bacarra A, Godowski P, Rosen E, Madara J . Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and.... J Clin Invest. 1994; 93(5):2056-65. PMC: 294323. DOI: 10.1172/JCI117200. View